Localize proximal weakness, interpret CK without mistaking it for strength, and select testing and treatment while recognizing urgent complications.
A person who struggles to stand may have injured muscle fibers, impaired nerve-to-muscle communication, or pain that limits force. Localize the weakness first. Then use creatine kinase to assess enzyme leakage, and check whether swallowing, breathing, heart rhythm or kidney function is at risk.
Find the weak muscles before interpreting the blood test
Does difficulty standing mean that the muscle fibers are injured? Not by itself. Proximal means nearer the trunk. Hip and shoulder weakness can make stairs, chair rise, overhead reaching and hair washing difficult. First establish an objective loss of force, then decide whether its distribution suggests muscle, nerve, neuromuscular transmission or pain-limited performance.
Picture a person who needs both arms to rise from a chair and cannot keep either arm above shoulder height. Bilateral hip flexion, shoulder abduction and neck flexion are weak, but ankle power and sensation are intact. This pattern favors a myopathy. Preserved reflexes support that interpretation but are not a requirement: advanced muscle disease can reduce them. A CK result adds evidence of fiber injury; it does not provide the localization by itself. [1][2]
Map the examination. On the body diagram, trace the shoulder and hip regions. Now add distal numbness and absent ankle reflexes to the same person. The sensory abnormality requires a broader explanation, often a peripheral neuropathy or a mixed disorder, rather than a pure proximal myopathy. Focal radiating pain with myotomal weakness and an asymmetric reflex suggests a nerve root. Fasciculations with upper or lower motor neuron findings require a motor neuron evaluation.
Identify the girdle distribution, then add the sensory and reflex examination before choosing a localization. Highlighted regions are a simplified functional map, not a diagnosis or an anatomical tracing. [1][14]
Intact sensation does not distinguish muscle disease from a neuromuscular junction disorder. Variable ptosis, diplopia or chewing fatigue that worsens with repeated use suggests impaired transmission, including myasthenia gravis. By contrast, a swollen painful shoulder that limits effort can appear weak even when the contractile apparatus is intact. Reassess force with the joint supported and pain accounted for; do not treat inconsistent effort as evidence that symptoms are unreal. [14]
Compare two examinations. In one patient, assisted positioning reduces pain and permits full force. In another, weakness persists during comfortable testing of several proximal groups. The first result supports pain-limited performance; the second establishes objective weakness requiring localization. Neither muscle tenderness nor its absence proves or excludes inflammation.
Apply the pattern to a new patient with normal sensation
Ask whether the deficit is fixed or fatigable, and examine the eyes, face, neck, reflexes and distal muscles. New diplopia with repeated gaze testing redirects the investigation toward transmission even when getting out of a chair is difficult. The preserved sensory examination alone is insufficient. [14]
Separate enzyme leakage from useful force
If two patients cannot climb stairs, must their CK values be similar? Creatine kinase (CK) is an intracellular enzyme involved in energy transfer. Serum CK reflects enzyme entry into blood and clearance from it. It is not a direct measurement of strength, muscle mass or the ability to swallow. Marked CK increases can accompany rhabdomyolysis, necrotizing autoimmune myopathy, dystrophy and other inflammatory muscle disorders; a number alone does not distinguish them. [1][3][6][9]
The fiber diagram contrasts a leaking cell with a smaller fiber that has little membrane leakage. Extensive necrosis can release much CK. Chronic glucocorticoid-related wasting can impair force with a normal CK. Some congenital, mitochondrial and long-standing fatty muscle disorders also produce little CK despite important disability. Dermatomyositis can be active with normal CK; in selected patients, aldolase and further muscle assessment expose the mismatch. Aldolase itself is not muscle-specific. [3][11][12]
Compare membrane leakage with fiber size and useful function. Predict how CK and chair-rise performance could differ before applying the new-exercise example. The drawing is qualitative, not a severity scale. [1][3][11][12]
Use the leakage-versus-function comparison. Consider a treated patient whose CK falls from 4,800 to 900 U/L while chair-rise assistance is unchanged. Place enzyme leakage and useful force on separate rows. The laboratory trend supports less enzyme release relative to clearance, but functional recovery has not yet been demonstrated. Compare with someone who has progressive weakness and CK 110 U/L: that second patient still needs an explanation. These are teaching examples, not diagnostic cutoffs.
Interpret a result against the reporting laboratory's upper limit of normal (ULN), with attention to its validated reference population, muscle mass, age, sex, recent activity and medicines. Strenuous exercise, trauma, seizures, intramuscular injections and recent needle testing can increase CK. Population differences exist, but ancestry should never be used to dismiss a symptomatic patient's findings. Review supplements and occupational exertion as well as prescriptions. [1]
For a stable adult with an incidental result and no objective weakness, dark urine or systemic illness, repeat CK after avoiding strenuous exercise for at least 72 hours, preferably a week. Persistent abnormality may need additional measurements and specialist investigation. The 2026 EAN guideline recommends investigation of persistent oligo/asymptomatic CK above 1.5 times an appropriate ULN. This is not a threshold for delaying care in a symptomatic patient. Medication changes should be agreed with the prescriber. [1]
Make a two-readout prediction. A recovering patient can now rise from a chair without using the arms. Before the next blood sample, the patient completes an unfamiliar intense workout. Predict whether a higher CK would erase the observed functional improvement, then compare the two readouts below.
Compare the function and enzyme interpretations
The exercise is a competing source of enzyme release. Repeat the clinical examination and interpret an appropriately timed repeat sample rather than declaring treatment failure from that isolated result. New pain, dark urine or systemic illness instead calls for prompt assessment. [1][9]
Let the skin, distribution and time course narrow the cause
Why do patients with similar CK values need different evaluations? Their muscles may be injured through different processes. Compare the location of weakness, the speed of progression, medicines, skin findings and other organs before choosing a disease label.
Read the clinical photograph. Identify the dorsal finger joints, then distinguish the raised red-to-violaceous lesions over those joints from the surrounding skin. These are Gottron papules, a characteristic dermatomyositis finding. The photograph shows one appearance on one person's skin; color and prominence vary. It cannot establish that every joint-centered rash is dermatomyositis. With objective proximal weakness, such lesions warrant a myositis assessment rather than treatment as isolated hand dermatitis. [2][3]
Find the raised joint-centered lesions before reading the surrounding skin. These joint-centered lesions are Gottron papules associated with dermatomyositis. This single appearance does not represent every skin tone or make every hand rash diagnostic. Image: Mohammad2018; original source; CC BY-SA 4.0.
Other dermatomyositis findings include a violaceous eruption around the eyelids (heliotrope rash) and photosensitive changes across the upper chest or back. Poikiloderma combines altered pigmentation, superficial dilated vessels and atrophy. Dysphagia or pulmonary symptoms are clinically important even if limb weakness seems modest. Characteristic skin disease without clinical muscle weakness can occur, and a normal CK does not by itself settle whether muscle involvement is present. [2][3]
Immune-mediated necrotizing myopathy (IMNM) often causes subacute, substantial proximal weakness with a large CK increase. Anti-HMGCR and anti-SRP are useful phenotype-directed antibodies. Anti-HMGCR disease can persist after statin withdrawal and can also occur without prior statin exposure. A biopsy may show prominent necrotic and regenerating fibers with relatively sparse inflammatory cells; sparse inflammation does not exclude an immune cause. [5][6]
Chronic steroid myopathy usually produces gradual, painless proximal weakness with normal or mildly high CK. The history of glucocorticoid exposure matters, but it should not end the evaluation when a new rash, marked enzyme rise or bulbar deficit suggests another process. Do not assume that weakness during treatment for inflammation always means the original disease is more active. [11][12]
Inclusion body myositis (IBM) more often evolves over years, with quadriceps and deep finger-flexor weakness that may be strikingly asymmetric. Falls and difficulty gripping can precede recognition. CK may be normal or only moderately increased despite substantial disability. Biopsy findings such as endomysial inflammation with rimmed vacuoles support the diagnosis when integrated with the clinical pattern; no single antibody or isolated tissue feature should replace that integration. [7][15]
Compare before naming. Both a rapidly weakening statin user and a person with years of asymmetric knee-extension and finger-flexion loss may have abnormal CK. The first tempo suggests active fiber injury; the second distribution suggests IBM. Changing only the CK value would not erase those differences.
Apply the skin finding to cancer assessment
In adult-onset dermatomyositis, combine routine age-appropriate screening with myositis-specific risk assessment. Subtype, anti-TIF1-gamma or other relevant antibodies, age, dysphagia and persistent disease activity influence additional testing. Cancer evaluation is risk-based, not the same automatic imaging package for every person with muscle weakness. [8]
Choose the test that answers the remaining question
Should every patient with proximal weakness go straight to biopsy? Begin with the missing information. Establish tempo, objective distribution, family history, recent infection, exercise, medicines, alcohol and supplements. Ask directly about swallowing, breathing and dark urine. These answers decide whether this is an outpatient diagnostic problem or an urgent organ-safety problem. [1][2][9]
Initial testing commonly includes CK, creatinine, electrolytes and urinalysis, with thyroid function and other tests selected from the history. Potassium, calcium, magnesium and phosphate disturbances can contribute to weakness. Aldolase can be useful when the phenotype suggests muscle disease despite normal CK. Inflammatory markers are nonspecific: normal results do not exclude myositis, and high results do not prove it. Infection testing and myositis antibodies should follow the clinical phenotype rather than substitute for it. [1][2][3]
AST and ALT can arise from skeletal muscle. A large CK increase with aminotransferases that follow the same course, without other evidence of liver injury, makes a muscular contribution plausible. This does not rule out coexisting liver disease. Bilirubin, liver-associated enzymes, medicines and the clinical setting help determine whether a separate hepatic evaluation is needed. [9]
Select a test by its job. Nerve conduction studies and electromyography help separate neuropathy, transmission failure and a myopathic motor-unit pattern. Muscle MRI shows distribution and helps distinguish active edema from fatty replacement. MRI edema is not specific for autoimmune inflammation. When biopsy is indicated, choose an accessible, affected muscle with enough viable tissue to answer the question, rather than an almost entirely fatty end-stage muscle or a site recently injured by a needle examination. [1]
Inherited or metabolic disease deserves attention when weakness is longstanding, relatives are affected, or episodes recur with particular exertional or fasting triggers. In an adult with persistent oligo/asymptomatic CK after acquired causes are addressed, current guidance favors MRI and appropriate genetic testing over routine first-line biopsy. That recommendation must not be transplanted uncritically into rapidly progressive suspected inflammatory disease, where tissue and antibody assessment may be needed sooner. [1]
Try the selection. A patient has fixed proximal weakness, but sensory loss makes a pure muscle disorder uncertain. Electrophysiology addresses localization. If localization is already muscular and MRI shows patchy viable, edematous tissue beside fatty replacement, the next question may instead be which site can provide a useful biopsy. The same test is not first for both patients.
Apply an unexpected laboratory result
A high aldolase with normal CK is a reason to revisit the muscle examination and other potential aldolase sources, not a diagnosis of dermatomyositis by itself. Objective weakness can justify further targeted muscle testing even though the first CK was reassuring. [3]
Identify the organ at risk before completing the differential
Which matters first: naming the myopathy or protecting the patient from its consequences? Acute muscle destruction can release potassium and myoglobin as well as CK. Hyperkalemia can disrupt cardiac conduction; myoglobin, reduced perfusion and tubular injury can contribute to acute kidney injury. Dark urine, severe muscle pain, a crush injury, prolonged immobilization, seizures or toxic exposure should prompt urgent assessment. The classic combination of pain, weakness and dark urine is not required. [9]
CK above five times the ULN or above 1,000 U/L is commonly used to support rhabdomyolysis in an appropriate acute setting. It is not a universal severity scale and is not interchangeable with a chronic myopathy diagnosis. CK may still be modest early after injury and commonly peaks over 24 to 72 hours. Check ECG, potassium, renal function, acid-base status and urine output; do not wait for the highest CK before treating dangerous physiology. A urine dipstick positive for blood with few red cells supports pigmenturia but does not alone distinguish myoglobin from hemoglobin. [9]
Trace the consequence. In the emergency diagram, follow potassium from the injured fiber to the heart, then follow pigment toward the kidney. If the ECG develops widening complexes during severe hyperkalemia, urgent intravenous calcium stabilizes cardiac excitability while potassium-shifting and elimination treatments are arranged. Calcium does not lower the potassium concentration. This is monitored emergency treatment, not an outpatient response to an isolated laboratory value. [9]
Choose the organ assessment for each released substance. Potassium creates an electrical threat; pigment contributes to kidney injury. CK is an injury marker, not the substance responsible for either depicted complication. [9]
Use isotonic crystalloid according to perfusion, urine output and congestion, with repeated reassessment. Saline or lactated Ringer's solution can be used; a fixed large-volume regimen is not appropriate for every patient. Persistent anuria or overload requires escalation, not indefinite fluid escalation. Routine bicarbonate or mannitol solely to prevent rhabdomyolysis-associated kidney injury is not recommended; other independent indications require their own assessment. [9]
A tense painful limb, pain out of proportion or pain with passive stretch also raises concern for compartment syndrome. Palpable pulses do not exclude it. Obtain urgent surgical assessment in parallel with resuscitation; do not wait for a CK trend to decide whether tissue is threatened. [13]
New dysphagia, choking, a weak cough, neck-flexor weakness or breathing difficulty can threaten swallowing and ventilation without an enormous CK. Obtain urgent swallowing and respiratory assessment; a normal oxygen saturation does not measure ventilatory reserve. Chest pain, arrhythmia, syncope or heart-failure findings need prompt cardiac evaluation. In inflammatory myopathy, cardiac troponin I is preferred over T for assessing cardiac injury because regenerating skeletal muscle may contribute to T. Neither biomarker replaces ECG and clinical assessment. [2]
Apply a falling CK to disposition
Compare kidney function, potassium, urine output, swallowing and respiratory status with the previous examination. A falling CK does not authorize discharge when one of those organ measures is worsening. Fever or suspected systemic infection also changes urgency independently of the CK value. [2][9]
Use treatment response to test the working explanation
What should change after the suspected exposure ends? The answer depends on whether injury depends on continuing exposure or is sustained by an immune process. Record both CK and function, including a reproducible chair-rise or strength assessment, before interpreting the trajectory.
For uncomplicated statin-associated aching with no severe weakness or organ injury, review exercise, hypothyroidism, dose and interacting drugs. A clinician-directed pause may help assess causality. After symptoms settle, a different statin or lower tolerated regimen, with nonstatin treatment when appropriate, can preserve cardiovascular protection. A single episode of muscle symptoms does not mean that all future lipid-lowering therapy should stop. Suspected severe myopathy or rhabdomyolysis requires immediate medication review and acute assessment instead. [4][5]
When substantial weakness and a large CK increase persist after statin withdrawal, assess for IMNM rather than repeatedly extending observation. Anti-HMGCR testing, specialist evaluation and sometimes biopsy help establish the diagnosis. Anti-SRP disease is another immune necrotizing phenotype. Immunotherapy is often needed, sometimes with multiple agents; routine statin rechallenge is not the appropriate experiment in suspected or established immune-mediated disease. [5][6]
Compare the two trajectories. Trace the solid and dashed curves in the treatment-response diagram. In the improving example, both CK and daily function recover after an exposure is addressed. In the persistent-injury example, CK remains high while functional ability worsens. These courses support different next questions; they do not prove an antibody result, impose an eight-week waiting rule or promise a particular recovery time.
Trace both plots before interpreting response to an exposure change. Persistent weakness and enzyme leakage need renewed assessment rather than a fixed waiting period. These are conceptual examples, not trial data, diagnostic thresholds or promised recovery times. [4][5][6]
For chronic steroid myopathy, coordinate a gradual dose reduction or steroid-sparing plan with the treating team while maintaining control of the underlying disease. Do not abruptly stop prolonged glucocorticoids. [17] Rehabilitation and adequate nutrition support recovery. Increasing glucocorticoids just because a patient is weaker can worsen medication-related wasting. [11][12]
Hypothyroid myopathy commonly has high CK; hyperthyroid weakness often has normal or only mildly abnormal CK. Correct the thyroid disorder and follow strength as well as laboratory results. Correct relevant electrolyte, infectious, toxic or nutritional causes rather than prescribing immunosuppression for every proximal pattern. [10]
Inflammatory myopathies need subtype- and severity-directed treatment, with ongoing evaluation of swallowing, lungs, heart and adult cancer risk. IBM should not be assumed to respond like other inflammatory myopathies: rehabilitation, falls prevention, assistive strategies and swallowing support remain important. Judge success by useful function and organ safety as well as enzyme results. [2][7][8][15][16]
Apply a mismatch during follow-up
If CK improves but falls become more frequent, reassess muscle damage, steroid exposure, neuropathy and other contributors to disability. Conversely, new large CK increases during otherwise stable function require investigation of active injury and exposures. Neither measure is a substitute for the other. [1][2][11]
Apply the examination and laboratory pattern
For each patient, identify the important findings and answer the clinical question before comparing the options.
Case 1
Show answer and explanations for case 1
A. Large, long-duration motor units with reduced recruitment (Why this does not fit)
Chronic denervation with reinnervation produces large motor units and reduced recruitment. The symmetric girdle pattern and substantial CK increase favor muscle fiber disease rather than a chronic neurogenic process.
Reasoning steps for option A
What motor-unit change produces large, long-duration units with reduced recruitment?
Reinnervation after chronic denervation enlarges the remaining motor units and lengthens their potentials, while loss of available units reduces recruitment.
Why does her symmetric girdle weakness with CK 2,640 argue against chronic denervation?
The symmetric girdle pattern and substantial CK increase favor muscle fiber disease rather than a chronic neurogenic process.
B. Small, short-duration motor units with early recruitment (Best answer)
Loss of functioning fibers within individual motor units produces a myopathic pattern with early recruitment. The fixed proximal deficits plus enzyme leakage favor a muscle process, making this the best expected pattern.
Reasoning steps for option B
Why would loss of functioning fibers yield small, short-duration units recruited early?
Loss of functioning fibers makes each motor unit smaller and its potential shorter; early recruitment compensates for reduced force per unit.
How do fixed girdle deficits and CK about 12 times ULN support this myopathic prediction?
The fixed proximal deficits plus enzyme leakage favor a muscle process, making this the best expected pattern.
C. Decreasing compound response during low-frequency stimulation (Why this does not fit)
A decrement can support impaired neuromuscular transmission. There is no fluctuating ocular or bulbar pattern, and the substantial CK increase supports fiber injury rather than isolated transmission failure.
Reasoning steps for option C
What does a decreasing compound response on low-frequency stimulation indicate?
A decrement can support impaired neuromuscular transmission.
Why do absent fluctuating ocular or bulbar symptoms and marked CK elevation weaken isolated transmission failure here?
There is no fluctuating ocular or bulbar pattern, and the substantial CK increase supports fiber injury rather than isolated transmission failure.
D. Reduced sensory amplitudes with distal conduction slowing (Why this does not fit)
Abnormal sensory responses support a peripheral nerve process. Sensation and distal strength are preserved, whereas the objective deficits are centered on the girdles.
Reasoning steps for option D
What localization would reduced sensory amplitudes and distal slowing imply?
Reduced sensory amplitudes and distal slowing indicate peripheral nerve involvement rather than a pure muscle process.
How do intact sensation, full distal power and proximal weakness oppose that nerve pattern?
Sensation and distal strength are preserved, whereas the objective deficits are centered on the girdles.
Takeaway: A CK result supports, but does not replace, localization from the examination. [1]
A. Failure of motor axon conduction from distal axonal loss (Why this does not fit)
Motor axon loss can reduce force and is often accompanied by neurogenic examination findings. The fluctuating ocular and chewing deficits with normal reflexes do not fit a fixed distal axonal pattern.
Reasoning steps for option A
How would distal motor axon loss affect force and the neurologic examination?
Distal motor axon loss causes a more fixed distal deficit and can produce neurogenic examination findings rather than rest-responsive fatigue.
Why do rest-responsive ptosis and chewing difficulty with preserved reflexes oppose fixed distal axonal loss?
The fluctuating ocular and chewing deficits with normal reflexes do not fit a fixed distal axonal pattern.
B. Reduced calcium-dependent acetylcholine release at the nerve terminal (Why this does not fit)
Presynaptic transmission failure can cause proximal weakness, often with autonomic symptoms and depressed reflexes. Normal reflexes, absent autonomic symptoms and prominent fatigable ocular findings favor a postsynaptic disorder.
Reasoning steps for option B
How can reduced presynaptic acetylcholine release cause proximal weakness?
Reduced calcium-dependent release leaves less acetylcholine available for muscle activation and can produce proximal weakness with autonomic symptoms and depressed reflexes.
What about her normal reflexes, absent dry mouth and prominent ocular fatigue favors postsynaptic over presynaptic failure?
Normal reflexes, absent autonomic symptoms and prominent fatigable ocular findings favor a postsynaptic disorder.
C. Loss of contractile fibers through diffuse myocyte necrosis (Why this does not fit)
Myocyte necrosis can cause fixed proximal weakness and CK leakage. Rest-responsive ocular weakness with normal CK is better explained by transmission failure than diffuse muscle necrosis.
Reasoning steps for option C
How could diffuse myocyte necrosis produce proximal weakness and CK leakage?
Necrosis destroys contractile fibers, making weakness fixed and releasing intracellular CK into blood.
Why do normal CK and ocular weakness relieved by rest argue against diffuse fiber necrosis?
Rest-responsive ocular weakness with normal CK is better explained by transmission failure than diffuse muscle necrosis.
D. Impaired acetylcholine signaling at the postsynaptic membrane (Best answer)
Reduced postsynaptic neuromuscular transmission causes fatigable weakness without primary sensory loss. The ocular, bulbar and proximal fatigue pattern with preserved reflexes favors myasthenia gravis.
Reasoning steps for option D
How does reduced postsynaptic acetylcholine signaling affect strength and sensation?
Reduced postsynaptic transmission causes use-dependent weakness with recovery after rest without primary sensory loss.
Which combination of gaze-induced ptosis, chewing fatigue, recovery after rest and preserved reflexes supports myasthenia gravis?
The ocular, bulbar and proximal fatigue pattern with preserved reflexes favors myasthenia gravis.
Takeaway: Normal sensation occurs in both myopathy and neuromuscular junction disease; the pattern of fatigability matters. [14]
A. Nerve conduction studies with needle electromyography (Best answer)
Electrophysiology can distinguish a neuropathic process from primary muscle disease. Distal-predominant weakness, sensory loss and absent ankle reflexes make nerve testing more informative than treating the modest post-exertional CK as proof of myositis.
Reasoning steps for option A
What localization can nerve conduction and needle examination distinguish from primary muscle disease?
Nerve conduction evaluates sensory and motor peripheral nerve function, while needle examination helps distinguish neurogenic from myopathic motor units.
Why do numb soles, distal weakness and absent ankle reflexes outweigh CK 460 after a hike when choosing this study?
Distal-predominant weakness, sensory loss and absent ankle reflexes make nerve testing more informative than treating the modest post-exertional CK as proof of myositis.
B. MRI of the hip and thigh muscles (Why this does not fit)
Muscle MRI can identify distribution of edema or fatty replacement in suspected myopathy. It does not directly resolve the sensory and reflex abnormalities that dominate this examination.
Reasoning steps for option B
What muscle changes could hip and thigh MRI characterize if myopathy were suspected?
MRI can map muscle edema and fatty replacement in a suspected myopathy, but does not directly measure peripheral sensory conduction.
Why would muscle imaging leave his sensory loss and absent ankle reflexes unresolved?
It does not directly resolve the sensory and reflex abnormalities that dominate this examination.
C. Biopsy of a proximal thigh muscle (Why this does not fit)
Biopsy can define selected muscle disorders after localization and clinical assessment. The strongest evidence points to nerve involvement; immediate muscle sampling is not the best first localization study.
Reasoning steps for option C
When can a proximal thigh biopsy help define a muscle disorder?
Biopsy can characterize a muscle disorder once the clinical distribution and testing support muscle as the dominant localization.
Why should distal sensory and reflex findings be localized before sampling thigh muscle?
The strongest evidence points to nerve involvement; immediate muscle sampling is not the best first localization study.
D. Myositis-specific serum antibody testing (Why this does not fit)
Antibodies can refine an inflammatory myopathy phenotype. The phenotype is distal and sensory rather than a pure inflammatory proximal pattern; the small CK increase after exertion is insufficient to override it.
Reasoning steps for option D
What diagnostic question can myositis antibodies refine?
Myositis antibodies can refine a clinically suspected inflammatory myopathy phenotype but do not localize distal sensory loss.
Why do distal sensory deficits and a modest post-hike CK rise make an inflammatory-muscle panel premature?
The phenotype is distal and sensory rather than a pure inflammatory proximal pattern; the small CK increase after exertion is insufficient to override it.
Takeaway: A slightly high CK should not erase clear sensory evidence for neuropathy. [1]
A. Perifascicular injury with microvascular inflammation (Why this does not fit)
Perifascicular injury is associated with dermatomyositis, which can occasionally have normal CK. The prolonged drug exposure and painless pattern without skin or bulbar findings favor steroid-related wasting over this inflammatory phenotype.
Reasoning steps for option A
What disorder can produce perifascicular injury despite occasionally normal CK?
Dermatomyositis can produce perifascicular injury through a microvascular inflammatory process, sometimes without elevated CK.
Why do five months of prednisone and absent rash or dysphagia favor steroid wasting over dermatomyositis here?
The prolonged drug exposure and painless pattern without skin or bulbar findings favor steroid-related wasting over this inflammatory phenotype.
B. Widespread necrosis with regenerating muscle fibers (Why this does not fit)
Necrotizing muscle disease can cause substantial proximal weakness. Active widespread necrosis would more often produce a large CK increase, unlike the normal enzymes and gradual course here.
Reasoning steps for option B
What proximal deficit can widespread necrosis of muscle fibers produce?
Why do gradual painless weakness and normal CK and aldolase oppose extensive active necrosis?
Active widespread necrosis would more often produce a large CK increase, unlike the normal enzymes and gradual course here.
C. Myofiber atrophy without prominent necrosis (Best answer)
Chronic glucocorticoid exposure can cause muscle wasting without extensive membrane injury. This explains painless proximal loss of force with normal CK after sustained prednisone exposure.
Reasoning steps for option C
Why can atrophic fibers reduce force without substantial CK release?
Chronic glucocorticoid exposure can cause muscle wasting without extensive membrane injury.
How does sustained prednisone exposure explain her painless girdle weakness and CK 82?
This explains painless proximal loss of force with normal CK after sustained prednisone exposure.
D. Endomysial inflammation with rimmed vacuoles (Why this does not fit)
This combination can support inclusion body myositis when the clinical distribution fits. The relatively recent symmetric girdle deficit does not match the characteristic years-long finger-flexor and quadriceps pattern.
Reasoning steps for option D
In which clinical distribution can endomysial inflammation and rimmed vacuoles support IBM?
Endomysial inflammation and rimmed vacuoles can support inclusion body myositis when weakness follows a chronic finger-flexor and quadriceps pattern.
Why does her recent symmetric girdle weakness differ from years of finger-flexor and quadriceps loss?
The relatively recent symmetric girdle deficit does not match the characteristic years-long finger-flexor and quadriceps pattern.
Takeaway: Loss of useful muscle force does not require a high serum CK. [11] [12]
A. Increase prednisone and reassess strength after a month (Why this does not fit)
More immunosuppression may help active inflammatory muscle disease. Normal enzymes, absent edema and controlled underlying disease instead support steroid-associated wasting; increasing exposure could worsen it.
Reasoning steps for option A
Under what competing explanation might increasing prednisone improve strength?
Escalating prednisone could treat active inflammatory muscle disease, but would not reverse glucocorticoid-related wasting.
Why do normal CK, MRI without edema and controlled thrombocytopenia make dose escalation potentially harmful?
Normal enzymes, absent edema and controlled underlying disease instead support steroid-associated wasting; increasing exposure could worsen it.
B. Reduce prednisone gradually and begin tailored rehabilitation (Best answer)
Reducing glucocorticoid exposure and rebuilding function address chronic steroid myopathy. A supervised taper preserves control of thrombocytopenia and limits adrenal risk, while rehabilitation addresses documented loss of muscle bulk.
Reasoning steps for option B
How does a gradual prednisone reduction address suspected medication-related atrophy?
A gradual taper reduces the exposure responsible for atrophy while allowing monitoring of thrombocytopenia and adrenal adaptation.
Why pair a supervised taper with rehabilitation after eight months of treatment and loss of muscle bulk?
A supervised taper preserves control of thrombocytopenia and limits adrenal risk, while rehabilitation addresses documented loss of muscle bulk.
C. Stop prednisone immediately and begin tailored rehabilitation (Why this does not fit)
Ending the offending exposure can help medication-related wasting. Abrupt cessation after many months risks adrenal insufficiency; the reduction needs a supervised plan.
Reasoning steps for option C
Why might stopping the offending steroid seem attractive for this weakness?
Removing glucocorticoid exposure could limit further medication-related atrophy, but cessation must account for adrenal suppression.
What risk of immediate withdrawal after eight months makes an abrupt stop inferior to a supervised taper?
Abrupt cessation after many months risks adrenal insufficiency; the reduction needs a supervised plan.
D. Keep prednisone unchanged and follow CK before rehabilitation (Why this does not fit)
CK trends can be useful in disorders with active fiber injury. CK is already normal in this atrophic pattern, so waiting for it to change does not address progressive functional impairment.
Reasoning steps for option D
When can serial CK usefully track treatment response in muscle disease?
Serial CK helps track fiber leakage in active destructive muscle disease; it need not track loss of muscle bulk.
Why is waiting for CK to rise or fall unhelpful when it is normal despite atrophy and weakness?
CK is already normal in this atrophic pattern, so waiting for it to change does not address progressive functional impairment.
Takeaway: Weakness during glucocorticoid treatment does not automatically justify a higher dose. [11] [12] [17]
A. Greater enzyme release with recovered functional strength (Why this does not fit)
Increasing enzyme release can accompany active fiber injury, while function may change independently. The measured CK has fallen and the examination has not improved, so neither part matches the supplied data.
Reasoning steps for option A
What would greater enzyme release and recovered strength each require as evidence?
Greater release would be supported by rising CK under stable clearance conditions, and recovered strength by improved objective hip power or chair rise.
Why do CK falling from 6,200 to 620 and unchanged assisted chair rise contradict both parts?
The measured CK has fallen and the examination has not improved, so neither part matches the supplied data.
B. Less enzyme release with recovered functional strength (Why this does not fit)
A lower CK can accompany biochemical improvement during treatment. The first part fits, but unchanged 3/5 power and assisted chair rise do not demonstrate recovered function.
Reasoning steps for option B
How does falling CK support less enzyme release relative to clearance?
A decline in CK with stable renal function and hydration supports reduced leakage relative to clearance, not necessarily improved force.
Why do 3/5 hip flexion and continued arm-assisted chair rise contradict recovered function?
The first part fits, but unchanged 3/5 power and assisted chair rise do not demonstrate recovered function.
C. Less enzyme release with persistent functional impairment (Best answer)
With stable clearance conditions, a sustained CK decline supports reduced enzyme release relative to clearance. Persistent weakness on the same functional assessment shows that biochemical improvement has not established strength recovery.
Reasoning steps for option C
With stable kidney function and hydration, what does the tenfold CK fall suggest?
The drop from 6,200 to 620 U/L with stable clearance conditions supports less enzyme release relative to clearance.
What do unchanged hip power and chair-rise assistance show despite biochemical improvement?
Persistent weakness on the same functional assessment shows that biochemical improvement has not established strength recovery.
D. Greater enzyme release with persistent functional impairment (Why this does not fit)
Ongoing active injury can coexist with poor function. The functional component fits, but the substantial CK fall under stable conditions does not support greater enzyme release.
Reasoning steps for option D
Why can persistent weakness coexist with ongoing enzyme release in principle?
Ongoing fiber injury and residual weakness can coexist because CK leakage and useful muscle force measure different processes.
Which part fits her unchanged function, and why does declining CK not support greater release here?
The functional component fits, but the substantial CK fall under stable conditions does not support greater enzyme release.
Takeaway: Follow CK and useful function together; improvement in one does not establish improvement in the other. [2] [3]
A. Obtain myositis antibodies at the current visit (Why this does not fit)
Targeted antibodies can help characterize a compatible inflammatory phenotype. No objective weakness or systemic phenotype is present, and recent unusual exertion offers a competing explanation that should be reassessed first.
Reasoning steps for option A
When are myositis antibodies useful for characterizing a muscle phenotype?
Myositis antibodies refine a suspected inflammatory phenotype after compatible weakness or systemic findings make it plausible.
Why do a normal strength examination and CK drawn after unusual lifting make antibodies premature?
No objective weakness or systemic phenotype is present, and recent unusual exertion offers a competing explanation that should be reassessed first.
B. Arrange a thigh biopsy using the current CK result (Why this does not fit)
Biopsy can help characterize selected persistent muscle abnormalities. One modest post-exertional result without weakness does not justify beginning with an invasive tissue test.
Reasoning steps for option B
What can a thigh biopsy clarify in selected persistent muscle abnormalities?
Biopsy can characterize selected muscle abnormalities after persistence and muscle localization warrant invasive assessment.
Why is one CK value of 570 after exercise without weakness insufficient to justify immediate biopsy?
One modest post-exertional result without weakness does not justify beginning with an invasive tissue test.
C. Obtain a muscle MRI before repeating laboratory testing (Why this does not fit)
MRI can reveal subclinical patterns in persistent hyperCKemia. Persistence has not been established and the sampling occurred immediately after unusual exercise.
Reasoning steps for option C
What could muscle MRI reveal in persistent unexplained hyperCKemia?
MRI may map edema or fatty change when CK elevation persists unexplained, but it cannot establish persistence from one sample.
Why should persistence be assessed before imaging a stable worker tested after his first heavy workout?
Persistence has not been established and the sampling occurred immediately after unusual exercise.
D. Repeat CK after a week without strenuous exercise (Best answer)
Exercise can transiently increase CK; rest and repeat testing help establish whether an abnormality persists. The patient is clinically stable without kidney or pigment findings, so a properly timed repeat is appropriate rather than an acute myopathy workup.
Reasoning steps for option D
How can unusual resistance exercise alter the next-morning CK result?
Unaccustomed heavy exercise can temporarily increase muscle enzyme leakage, raising CK in a sample drawn the next morning.
Why do normal urine, creatinine, potassium and strength permit repeating CK after a week of rest?
The patient is clinically stable without kidney or pigment findings, so a properly timed repeat is appropriate rather than an acute myopathy workup.
Takeaway: Resting-repeat guidance applies to clinically stable incidental findings, not to dangerous symptoms. [1]
A. Begin thyroid hormone replacement with clinical follow-up (Best answer)
Hypothyroidism can cause proximal weakness and increased CK. The high TSH, low free T4 and systemic findings identify a treatable endocrine cause; strength and CK should be reassessed with treatment.
Reasoning steps for option A
How do TSH 48 and free T4 0.3 identify a treatable endocrine cause?
A high TSH paired with low free T4 indicates primary hypothyroidism, a treatable cause of proximal weakness and CK elevation.
Why should thyroid replacement be followed by reassessment of both CK 1,160 and proximal strength?
The high TSH, low free T4 and systemic findings identify a treatable endocrine cause; strength and CK should be reassessed with treatment.
B. Begin high-dose glucocorticoids for inflammatory muscle injury (Why this does not fit)
Glucocorticoids treat many active immune-mediated myopathies. The enzyme increase is not specific for inflammation, and the supplied endocrine results provide a more direct explanation.
Reasoning steps for option B
What muscle condition might justify high-dose glucocorticoids?
High-dose glucocorticoids may treat active immune-mediated myopathy, but CK elevation alone does not establish immune injury.
Why does high CK alone not outweigh cold intolerance, delayed reflex relaxation and confirmed hypothyroidism?
The enzyme increase is not specific for inflammation, and the supplied endocrine results provide a more direct explanation.
C. Begin intravenous immunoglobulin for necrotizing muscle disease (Why this does not fit)
Immunoglobulin may be used for selected severe immune muscle disease. No supporting immune phenotype is supplied, while untreated primary hypothyroidism is objectively established.
Reasoning steps for option C
When might intravenous immunoglobulin be considered for immune muscle disease?
Intravenous immunoglobulin can be used for selected severe immune muscle disease, including some necrotizing phenotypes, when the phenotype supports it.
Why is necrotizing disease less supported than untreated primary hypothyroidism in this presentation?
No supporting immune phenotype is supplied, while untreated primary hypothyroidism is objectively established.
D. Begin pyridostigmine for impaired neuromuscular transmission (Why this does not fit)
Pyridostigmine can improve symptoms of some postsynaptic transmission disorders. There is no fatigable ocular or bulbar pattern; systemic thyroid findings and CK leakage support an endocrine muscle process.
Reasoning steps for option D
Which transmission disorder can respond symptomatically to pyridostigmine?
Postsynaptic myasthenia gravis can respond symptomatically to pyridostigmine because it improves acetylcholine availability at the neuromuscular junction.
Why do absent fatigable ocular or bulbar symptoms and overt thyroid dysfunction oppose this approach?
There is no fatigable ocular or bulbar pattern; systemic thyroid findings and CK leakage support an endocrine muscle process.
Takeaway: A high CK does not make an inflammatory cause more likely than a well-supported endocrine explanation. [10]
A. Hypokalemic paralysis from an intracellular potassium shift (Why this does not fit)
Thyrotoxicosis can accompany episodic weakness caused by a potassium shift. The deficit is persistent rather than episodic and the measured potassium is normal; the data do not establish hypokalemic paralysis.
Reasoning steps for option A
How can thyrotoxicosis precipitate weakness through an intracellular potassium shift?
In thyrotoxic periodic paralysis, intracellular potassium shifting produces episodic low serum potassium and transient weakness.
Why do persistent weakness and potassium 4.2 fail to establish episodic hypokalemic paralysis?
The deficit is persistent rather than episodic and the measured potassium is normal; the data do not establish hypokalemic paralysis.
B. Thyroid-related muscle dysfunction with little enzyme leakage (Best answer)
Thyroid excess can impair muscle function without a proportional increase in serum CK. The hormone results and systemic findings explain persistent proximal weakness despite a normal CK concentration.
Reasoning steps for option B
How can thyroid excess impair proximal force while CK remains normal?
Thyroid excess can reduce useful muscle force without extensive fiber membrane injury, so CK need not increase.
How do suppressed TSH, high free T4, weight loss and heat intolerance support this explanation for CK 120?
The hormone results and systemic findings explain persistent proximal weakness despite a normal CK concentration.
C. Necrotizing inflammatory myopathy with substantial fiber injury (Why this does not fit)
Necrotizing immune muscle disease often causes fixed proximal weakness. Normal CK and a clear thyrotoxic syndrome make extensive necrotizing injury a less coherent explanation.
Reasoning steps for option C
Why might necrotizing inflammatory disease cause fixed proximal weakness?
Extensive necrotizing injury can cause fixed proximal weakness by destroying fibers and generally leaks substantial CK.
Why do normal CK and the overt thyrotoxic syndrome make substantial fiber necrosis less coherent?
Normal CK and a clear thyrotoxic syndrome make extensive necrotizing injury a less coherent explanation.
D. Postsynaptic transmission failure with use-dependent fatigability (Why this does not fit)
A neuromuscular junction disorder can cause weakness with normal CK. The supplied examination lacks fatigability or ocular involvement and instead accompanies overt thyroid excess.
Reasoning steps for option D
Why might postsynaptic transmission failure leave CK normal?
Impaired postsynaptic transmission weakens activation without primarily injuring muscle fibers, so CK can remain normal.
Why do nonfluctuating strength and absent ocular fatigue favor thyroid-related muscle dysfunction instead?
The supplied examination lacks fatigability or ocular involvement and instead accompanies overt thyroid excess.
Takeaway: Thyroid excess can reduce force without a large CK increase. [10]
A. Repeat CK alone after three months of observation (Why this does not fit)
Repeated CK can clarify an isolated laboratory abnormality in an otherwise well patient. This patient already has objective progressive weakness and characteristic skin findings; CK alone would inadequately assess the active phenotype.
Reasoning steps for option A
When is delayed CK repetition a reasonable first move?
For an otherwise well person with an isolated CK abnormality, repeating the result can clarify persistence.
Why does a CK of 155 U/L not justify three months of observation here?
She already has progressive objective girdle weakness and joint-centered violaceous papules; normal CK does not exclude active muscle disease.
B. Use aldolase to establish the subtype without further evaluation (Why this does not fit)
Aldolase can detect muscle injury when CK is normal. It is not subtype-specific and has nonmuscular sources, so it cannot by itself establish a dermatomyositis diagnosis.
Reasoning steps for option B
What does aldolase 15 U/L add when CK is within range?
It supports possible muscle injury despite normal CK, although aldolase also has nonmuscular sources.
Can that aldolase result alone name her myositis subtype?
No. It is not subtype-specific; the papules and weakness require phenotype-directed assessment rather than diagnosis from aldolase alone.
C. Evaluate muscle with MRI or electrophysiology (Best answer)
A compatible examination can justify further muscle evaluation despite normal CK. The combination of objective proximal weakness, joint-centered papules and high aldolase supports additional phenotype-directed assessment, with biopsy as appropriate.
Reasoning steps for option C
Which examination findings make targeted muscle testing appropriate despite CK 155 U/L?
Symmetric objective proximal weakness together with Gottron-like joint-centered papules suggests a dermatomyositis-compatible phenotype.
How could MRI or electrophysiology address the remaining uncertainty?
They can assess muscle involvement and localization despite normal CK; biopsy can follow when appropriate, while high aldolase remains supportive rather than diagnostic.
D. Investigate skin disease separately from the strength findings (Why this does not fit)
An isolated dermatosis can coexist with unrelated fatigue. Here force is objectively reduced in a myopathic pattern, so separating the findings solely because CK is normal would miss a plausible unified disorder.
Reasoning steps for option D
Could the dorsal finger papules represent an isolated skin disorder?
An isolated dermatosis is possible in general and could coexist with unrelated fatigue.
What argues against separating the rash from weakness in this woman?
Measured hip and shoulder power is reduced in a myopathic distribution, so normal CK is insufficient to dismiss a unifying muscle and skin process.
Takeaway: Normal CK does not exclude a treatable inflammatory myopathy when the examination is convincing. [2] [3]
A. Grouped atrophy with fiber-type grouping (Why this does not fit)
Denervation followed by reinnervation can produce grouped atrophy and fiber-type grouping. Progressive symmetric girdle weakness with very high CK after medication withdrawal favors active muscle fiber injury over a chronic neurogenic process.
Reasoning steps for option A
What produces grouped atrophy and fiber-type grouping on biopsy?
Chronic denervation with reinnervation produces that neurogenic pattern.
Why is a chronic neurogenic pattern less persuasive for his rising CK?
Symmetric proximal weakness progresses after atorvastatin withdrawal while CK climbs from 7,800 to 9,600 U/L, favoring ongoing fiber injury.
B. Selective fiber atrophy without substantial necrosis (Why this does not fit)
A non-necrotizing atrophic process can reduce force while producing little enzyme leakage. The rising CK near fifty times the ULN is poorly explained by isolated atrophy.
Reasoning steps for option B
How can selective atrophy weaken a patient without major CK release?
Loss of functional fiber bulk can reduce force while little membrane injury releases enzyme.
Does selective atrophy without necrosis explain CK 9,600 U/L here?
Not well: this rising value is near 48 times the 200 U/L ULN and points to substantial active injury.
C. Perifascicular atrophy with prominent capillary injury (Why this does not fit)
This pattern supports dermatomyositis in a compatible clinical setting. The persistent post-statin course without characteristic skin findings more strongly suggests a necrotizing autoimmune phenotype.
Reasoning steps for option C
Which disease can show perifascicular atrophy and capillary injury?
Those tissue findings support dermatomyositis when the clinical context fits.
What makes that biopsy prediction weaker in this statin-exposed man?
He has no characteristic rash, and weakness and CK continue to worsen after statin cessation, favoring a necrotizing autoimmune phenotype instead.
D. Necrosis and regeneration with sparse inflammation (Best answer)
Immune-mediated necrotizing myopathy can have extensive fiber injury despite relatively few inflammatory cells. Persistent progressive weakness and rising CK after statin withdrawal support this process rather than uncomplicated statin-associated symptoms.
Reasoning steps for option D
What tissue pattern follows from ongoing fiber destruction despite few infiltrating cells?
Necrotic and regenerating fibers with sparse inflammation are compatible with immune-mediated necrotizing myopathy.
Why predict that pattern seven weeks after atorvastatin withdrawal?
His weakness still progresses and CK rises from 7,800 to 9,600 U/L without another supplied cause, rather than resolving as uncomplicated exposure-related symptoms might.
Takeaway: Sparse inflammatory cells do not exclude an immune cause of muscle necrosis. [5] [6]
A. Arrange prompt specialist-directed immunotherapy (Best answer)
Anti-HMGCR-associated necrotizing myopathy may require immunotherapy even after the statin is stopped. Persistent disabling weakness, high CK, positive antibodies and compatible tissue establish an immune process that withdrawal alone has not controlled.
Reasoning steps for option A
What does anti-HMGCR positivity plus necrosis and regeneration establish in this setting?
Together with disabling weakness and CK 11,200 U/L after statin withdrawal, these findings establish an immune-mediated necrotizing process.
Why arrange immunotherapy now instead of relying on withdrawal?
Stopping the statin has not controlled active weakness and injury; specialist-directed immune treatment is needed, with organ status monitored and supportive care.
B. Observe for another two months without disease-directed treatment (Why this does not fit)
Observation can clarify improving uncomplicated medication-associated symptoms. The patient is worsening with established immune-mediated necrosis, so further observation alone leaves active disease untreated.
Reasoning steps for option B
When might observation after stopping a statin be reasonable?
Improving uncomplicated medication-associated symptoms can be reassessed during a supervised interval.
Why is another untreated two-month interval unsafe as the sole plan here?
She needs help standing and has high CK, anti-HMGCR positivity and necrotizing biopsy despite withdrawal, so immune injury remains active.
C. Restart a lower-dose statin to test reproducibility (Why this does not fit)
A supervised rechallenge can assess causality after uncomplicated symptoms resolve. That approach is not appropriate for confirmed anti-HMGCR-associated disease with ongoing weakness and necrosis.
Reasoning steps for option C
What question can a supervised statin rechallenge answer in uncomplicated symptoms?
After symptoms resolve, it can help identify whether a statin regimen is tolerated or reproduces symptoms.
Why not test reproducibility with a lower statin dose in this patient?
Her persistent weakness, anti-HMGCR antibodies and necrotizing tissue already identify immune-mediated disease, for which routine rechallenge is inappropriate.
D. Begin rehabilitation as the sole treatment (Why this does not fit)
Rehabilitation supports function across many muscle disorders. It does not by itself treat the ongoing immune-mediated injury demonstrated here and should accompany rather than replace disease-directed care.
Reasoning steps for option D
What benefit could rehabilitation offer someone who needs help standing?
It can support mobility and function during recovery from muscle disease.
Why can rehabilitation not be her only treatment?
Exercise support does not suppress the established anti-HMGCR-associated necrotizing injury that persists after statin withdrawal; it should complement disease-directed therapy.
Takeaway: Confirmed immune-mediated muscle injury is not managed by repeated statin withdrawal experiments. [5] [6]
A. Resume the same high dose without symptom follow-up (Why this does not fit)
A high-intensity statin regimen can provide substantial cardiovascular protection. Reusing the regimen unchanged without monitoring ignores a reproducible dose-related symptom history.
Reasoning steps for option A
Why is maintaining intensive lipid lowering attractive after a prior myocardial infarction?
He has substantial ongoing cardiovascular risk, so preserving effective preventive therapy matters.
What is missed by restarting atorvastatin at the same high dose without follow-up?
His thigh aching followed dose escalation and resolved during a supervised pause; unchanged unmonitored dosing disregards that reproducible history.
B. Try a lower-dose or different statin regimen (Best answer)
A structured retrial can identify tolerated statin exposure after uncomplicated symptoms resolve. Preserving tolerated lipid-lowering therapy, with nonstatin treatment when needed, addresses his high cardiovascular risk without dismissing the symptoms.
Reasoning steps for option B
What separates his symptom episode from established immune necrotizing myopathy?
Strength and CK are normal, symptoms resolved with the clinician-supervised pause, and there is no persistent immune muscle phenotype.
How does a different or lower statin regimen address both competing needs?
A structured monitored retrial seeks tolerable statin exposure for his post-infarction risk, adding nonstatin lipid lowering if needed without dismissing symptoms.
C. Avoid lipid-lowering treatment despite persistent high risk (Why this does not fit)
Avoiding a medicine can prevent recurrence of a drug-related symptom. One uncomplicated episode does not establish that every statin or other lipid-lowering treatment is unsuitable.
Reasoning steps for option C
What symptom could stopping lipid medication altogether prevent?
Avoiding the suspected dose could prevent recurrence of his thigh aching.
Why is permanent avoidance of all lipid lowering disproportionate?
A single uncomplicated episode with normal strength and CK does not rule out other statin regimens or nonstatin treatment, while his prior infarction sustains high risk.
D. Begin immune suppression before further lipid treatment (Why this does not fit)
Immune suppression is used for confirmed immune-mediated muscle injury. Normal strength and CK with symptom resolution after a pause do not support that phenotype.
Reasoning steps for option D
When would immune suppression be justified for statin-associated weakness?
It is considered for established immune-mediated muscle injury rather than uncomplicated aching.
Do his examination, CK and response to withdrawal support immune therapy?
No. Strength and CK are normal and symptoms resolved during the pause, without persistent progressive injury to treat immunologically.
Takeaway: An uncomplicated symptom episode is a reason for structured reassessment, not abandonment of cardiovascular prevention. [4] [5]
A. Accelerated renal elimination of atorvastatin (Why this does not fit)
Altered elimination can change drug exposure and clinical effects. Faster elimination would reduce exposure rather than explain new toxicity shortly after clarithromycin was introduced.
Reasoning steps for option A
If atorvastatin elimination accelerated, which way would its exposure change?
Faster elimination would generally lower atorvastatin exposure, not increase it.
Why does that direction fail to explain symptoms five days after clarithromycin?
Acute pain, weakness, dark urine and CK 14,600 U/L followed the new medication after years of tolerance, fitting increased toxicity rather than reduced exposure.
B. Increased thyroid hormone clearance with hormone deficiency (Why this does not fit)
Hypothyroidism can predispose to weakness and statin-associated muscle injury. The timing is tied to a known drug interaction, while no new thyroid deficiency is demonstrated.
Reasoning steps for option B
Why consider thyroid deficiency in a statin user with weakness?
Hypothyroidism can contribute to weakness and susceptibility to statin muscle injury.
What makes increased thyroid hormone clearance an unsupported trigger here?
Thyroid function was normal last month and no new deficiency is shown; the abrupt onset instead follows addition of a known interacting antibiotic.
C. Inhibition of CYP3A4-mediated atorvastatin metabolism (Best answer)
Clarithromycin inhibits CYP3A4 and can increase atorvastatin exposure. New symptoms after clarithromycin is added to a high atorvastatin dose fit an interaction-related increase in muscle toxicity.
Reasoning steps for option C
What does clarithromycin do to CYP3A4-mediated atorvastatin metabolism?
It inhibits CYP3A4, potentially increasing exposure to atorvastatin at his 80 mg daily dose.
How does higher exposure connect this timeline to muscle injury?
After years without symptoms, severe pain, weakness, pigment-colored urine and markedly elevated CK appeared within five days of clarithromycin, consistent with interaction-related toxicity.
D. Induction of CYP3A4-mediated atorvastatin metabolism (Why this does not fit)
Induction of a metabolic pathway can lower exposure to its substrates. Clarithromycin is an inhibitor rather than an inducer, and reduced exposure would not explain the temporal toxicity pattern.
Reasoning steps for option D
What would CYP3A4 induction predict for atorvastatin levels?
Inducing its metabolism would tend to lower atorvastatin exposure.
Why is induction the wrong mechanism for the newly added clarithromycin?
Clarithromycin inhibits rather than induces CYP3A4, and decreased exposure does not account for the abrupt severe muscle toxicity.
Takeaway: Review newly added interacting medicines, not only the date the statin was first prescribed. [5]
A. Myofiber atrophy without prominent inflammation (Why this does not fit)
Glucocorticoid-related wasting can produce selective fiber atrophy and proximal weakness. The years-long asymmetric knee-extension and finger-flexion pattern is more characteristic of inclusion body myositis.
Reasoning steps for option A
Which weakness pattern might accompany isolated myofiber atrophy?
Glucocorticoid-related wasting can cause predominantly proximal weakness with selective atrophy.
Why does atrophy alone fit his distribution poorly?
Over four years he developed asymmetric quadriceps and deep finger-flexor loss, a characteristic inclusion body myositis pattern rather than generic proximal wasting.
B. Perifascicular atrophy with capillary abnormalities (Why this does not fit)
Perifascicular injury can support dermatomyositis. The selective asymmetric distal and quadriceps involvement is a closer fit to inclusion body myositis than a typical dermatomyositis distribution.
Reasoning steps for option B
What condition is supported by perifascicular atrophy and capillary abnormalities?
Those findings can support dermatomyositis in a fitting clinical phenotype.
Does his quadriceps and finger-flexor pattern favor that phenotype?
No. Unequal knee-extension loss and deep finger-flexor weakness over years fit inclusion body myositis more closely than typical dermatomyositis.
C. Diffuse necrosis with many regenerating fibers (Why this does not fit)
Necrotizing myopathy can cause prominent weakness with evidence of fiber injury. The slow selective course and modest CK are less consistent with an active diffuse necrotizing phenotype.
Reasoning steps for option C
What process yields diffuse necrosis and numerous regenerating fibers?
Active necrotizing myopathy can produce widespread fiber destruction and repair with marked weakness.
How do tempo and CK weigh against diffuse active necrosis here?
Four years of selective asymmetric decline and CK only 510 U/L favor inclusion body myositis over a diffuse rapidly injurious necrotizing process.
D. Endomysial inflammation with rimmed vacuoles (Best answer)
Endomysial inflammation and rimmed vacuoles support inclusion body myositis when the clinical pattern fits. The selective quadriceps and finger-flexor weakness, asymmetry and prolonged course provide that clinical context.
Reasoning steps for option D
What biopsy combination supports inclusion body myositis?
Endomysial inflammation with rimmed vacuoles supports IBM when interpreted alongside the examination, not in isolation.
Which features make those findings particularly informative in this man?
Years of falls and grip difficulty, asymmetric knee-extension and deep finger-flexor weakness, preserved sensation and modest CK form the compatible clinical context.
Takeaway: IBM diagnosis integrates the muscle pattern and tissue findings; no isolated biopsy feature is a substitute. [7] [15]
A. Arrange falls-focused rehabilitation and swallowing assessment (Best answer)
Supportive rehabilitation and swallowing care are central to managing disability and aspiration risk in IBM. New falls and meal-related coughing require functional and swallowing assessment despite a relatively stable CK.
Reasoning steps for option A
Which new IBM symptoms signal functional and swallowing hazards?
Twice-monthly falls indicate mobility risk, and coughing during meals raises swallowing and aspiration concerns.
Why act despite CK staying near 420 U/L?
CK tracks leakage rather than disability; falls-focused rehabilitation and swallowing assessment address her worsening function and safety directly.
B. Increase glucocorticoids until CK reaches the normal range (Why this does not fit)
Glucocorticoids help several other inflammatory myopathy subtypes. IBM is not reliably steroid-responsive, and normalizing this stable modest CK is not an appropriate substitute for addressing falls and swallowing.
Reasoning steps for option B
Why might clinicians use glucocorticoids in other inflammatory myopathies?
Some inflammatory subtypes respond to immune suppression with glucocorticoids.
Why not escalate steroids to normalize CK in this established IBM case?
IBM is not reliably steroid-responsive, and her stable modest CK is not a meaningful substitute for managing falls and meal-related coughing.
C. Continue observation until CK rises substantially (Why this does not fit)
A biochemical increase can indicate changing muscle injury in some disorders. IBM-related disability can progress with modest CK; waiting ignores current injury and aspiration risks.
Reasoning steps for option C
Does unchanged CK exclude progression of inclusion body myositis?
No. IBM-related loss of useful force and swallowing function may worsen with little change in enzyme leakage.
What harm follows from waiting for a major CK rise?
It postpones assessment of recurrent falls and coughing with meals, both present safety risks regardless of the next enzyme value.
D. Prescribe strict bed rest until strength improves (Why this does not fit)
Temporary rest can be useful after some acute injuries. The problem is chronic progressive disability; prolonged inactivity does not address safe mobility or swallowing and may worsen deconditioning.
Reasoning steps for option D
When might short-term rest help a muscle patient?
Temporary rest can have a role after certain acute injuries.
Why is strict bed rest counterproductive for her chronic IBM?
It neither prevents aspiration nor builds safer mobility and may add deconditioning to her progressive knee and finger weakness.
Takeaway: In IBM, functional decline and swallowing symptoms can require action without a large CK increase. [16]
A. Chest imaging directed solely at thymic disease (Why this does not fit)
Thymic assessment is relevant to selected patients with myasthenia gravis. Her established skin-and-muscle phenotype and antibody profile concern dermatomyositis-associated cancer risk rather than an isolated transmission disorder.
Reasoning steps for option A
In which neuromuscular condition might thymic imaging answer a focused question?
Selected patients with myasthenia gravis warrant evaluation of thymic disease.
Why does thymus-only imaging miss this woman's key risk?
Her hand and eyelid eruptions, proximal weakness and anti-TIF1-gamma positivity establish a dermatomyositis context with broader malignancy risk, not isolated transmission failure.
B. Cancer assessment only if routine screening becomes overdue (Why this does not fit)
Routine population screening remains important for adults with myositis. Age, dermatomyositis subtype, anti-TIF1-gamma positivity and dysphagia supply additional risk information even when routine screening is current.
Reasoning steps for option B
What role does routine breast and colorectal screening still play?
Up-to-date population screening remains an important component of cancer prevention in adults with myositis.
Why is waiting until that screening is overdue insufficient here?
New adult dermatomyositis at 52, anti-TIF1-gamma positivity and dysphagia add subtype-specific risk despite current routine tests.
C. Myositis-specific cancer risk assessment and additional screening (Best answer)
Myositis cancer guidance combines subtype, antibodies and clinical features with routine population screening. Her adult-onset dermatomyositis, age, antibody and dysphagia support a higher-risk evaluation rather than routine screening alone.
Reasoning steps for option C
Which features call for myositis-specific cancer risk stratification?
Adult-onset dermatomyositis after 40, anti-TIF1-gamma positivity and moderate dysphagia together support a higher-risk assessment.
How should that stratification change evaluation beyond current routine screening?
Arrange additional risk-informed malignancy evaluation tailored to her subtype, antibody and clinical features, rather than treating completed breast and colorectal tests as sufficient.
D. The same whole-body testing schedule used for every myopathy (Why this does not fit)
A systematic approach can reduce overlooked malignancy risk. Uniform testing ignores the important differences among myositis subtypes and individual risk features; this evaluation should follow a risk-based plan.
Reasoning steps for option D
Why might uniform whole-body testing sound appealing in myopathy?
A standardized search could appear to reduce the chance of overlooking a malignancy.
Why should her cancer workup not follow the same schedule as every myopathy?
Cancer risk differs across myositis subtypes and individuals; her anti-TIF1-gamma-positive dermatomyositis and dysphagia require risk-based rather than universal testing.
Takeaway: Current routine screening does not eliminate the need for myositis-specific cancer risk assessment. [8]
A. Intravenous insulin with glucose (Why this does not fit)
Insulin shifts potassium into cells and is important for treating severe hyperkalemia. It lowers extracellular potassium but is not the intervention that directly and immediately stabilizes cardiac excitability while other treatments take effect.
Reasoning steps for option A
How does intravenous insulin with glucose change severe hyperkalemia?
It shifts potassium into cells and helps lower extracellular potassium while definitive management proceeds.
Why does insulin not answer the widened-QRS stabilization question?
It does not directly stabilize cardiac excitability immediately; this ECG threat requires intravenous calcium in parallel with potassium-shifting therapy.
B. Intravenous calcium gluconate (Best answer)
Intravenous calcium counters the dangerous electrophysiologic effects of severe hyperkalemia. The widened QRS requires urgent stabilization while potassium-shifting and elimination treatment proceed; calcium itself does not reduce the potassium concentration.
Reasoning steps for option B
What immediate electrical problem does QRS widening at potassium 6.8 mmol/L indicate?
Severe hyperkalemia from acute muscle destruction is destabilizing cardiac conduction and poses an immediate arrhythmia threat.
What does intravenous calcium gluconate do, and what does it not do?
It promptly stabilizes the cardiac membrane against hyperkalemia's effects, but does not lower serum potassium; shifting and elimination still must proceed.
C. Nebulized albuterol (Why this does not fit)
A beta-2 agonist can promote intracellular potassium uptake as an adjunct. Its role is potassium shifting, not direct immediate membrane stabilization in this ECG emergency.
Reasoning steps for option C
How can nebulized albuterol contribute to treatment of potassium 6.8 mmol/L?
Beta-2 stimulation promotes potassium movement into cells and may serve as an adjunct.
Why is albuterol not the immediate answer to markedly widened QRS complexes?
Its effect is potassium shifting, not direct cardiac membrane stabilization; intravenous calcium addresses the electrical instability now.
D. Urgent hemodialysis (Why this does not fit)
Dialysis can eliminate potassium when indicated by severe or refractory abnormalities and kidney failure. It may be required, but arranging elimination does not replace immediate calcium for the current electrical instability.
Reasoning steps for option D
When may dialysis matter after immobilization with CK 68,000 U/L?
With kidney injury and severe or refractory hyperkalemia, dialysis can eliminate potassium when indicated.
Why not rely on hemodialysis arrangement for the present ECG changes?
Dialysis can remove potassium but cannot replace immediate intravenous calcium for markedly widened QRS while elimination is organized.
Takeaway: Calcium stabilizes the hyperkalemic heart; separate treatments shift or eliminate potassium. [9]
A. Obtain CT angiography before requesting a surgical assessment (Why this does not fit)
Arterial imaging can help when a major arterial injury is suspected. Warmth and palpable pulses do not exclude compartment syndrome, and the clinical compartment findings warrant urgent surgical assessment without waiting for routine arterial imaging.
Reasoning steps for option A
When would CT angiography clarify this compressed leg?
It could help if a major arterial injury were suspected.
Why should warm skin and palpable pedal pulses not delay the surgeon?
Neither excludes compartment syndrome; tense calf and passive-stretch pain warrant urgent surgical assessment without routine arterial imaging.
B. Wait for the next CK value to establish tissue injury (Why this does not fit)
Serial CK helps follow muscle injury over time. The tense compartment and pain with passive stretch already indicate a time-sensitive tissue threat; a later CK cannot safely determine whether to seek assessment.
Reasoning steps for option B
What information could another CK measurement provide after compression?
Serial CK can track the course of muscle injury.
Why is waiting for that result unsafe with passive dorsiflexion pain?
The tense compartment and stretch pain already signal a time-sensitive tissue threat that CK cannot adjudicate promptly.
C. Reassess after pulses become weak or absent (Why this does not fit)
Loss of a pulse can occur with severe arterial compromise. Pulses often remain present in compartment syndrome, so waiting for pulse loss delays evaluation of threatened muscle and nerve.
Reasoning steps for option C
What vascular change might absent pedal pulses indicate?
Pulse loss can signal severe arterial compromise.
Why are currently palpable pulses not a safe trigger for observation?
Compartment pressure can threaten muscle and nerve while distal pulses remain present; waiting for pulse loss delays assessment.
D. Request urgent surgical assessment for compartment syndrome (Best answer)
Raised pressure within a closed compartment can compromise tissue perfusion despite palpable distal pulses. The compression history, tense calf and pain with passive stretch require urgent surgical evaluation in parallel with systemic rhabdomyolysis care.
Reasoning steps for option D
How can a closed calf compartment threaten tissue despite a warm foot?
Elevated compartment pressure can impair local perfusion even with palpable large-artery pulses.
What should compression, calf tension and passive-stretch pain prompt now?
Urgent surgical evaluation for compartment syndrome should proceed alongside systemic rhabdomyolysis care.
Takeaway: Palpable distal pulses do not exclude a threatened compartment. [13] [9]
A. Kidney and electrolyte deterioration still require monitored treatment (Best answer)
Rhabdomyolysis severity depends on organ consequences as well as the CK trajectory. The falling enzyme concentration does not negate worsening oliguria, kidney injury and hyperkalemia, which require continued monitored assessment and treatment.
Reasoning steps for option A
Does a halving of CK measure recovery of kidney function?
No. CK tracks enzyme leakage, while rhabdomyolysis severity also depends on organ consequences.
What do creatinine 2.8, urine output 0.2 mL/kg/hour and potassium 6.1 require?
Worsening kidney injury, oliguria and hyperkalemia require continued monitored treatment despite falling CK.
B. The CK decline establishes readiness for outpatient follow-up (Why this does not fit)
A CK decline can support biochemical improvement once injury has peaked. It does not establish organ recovery; the renal and electrolyte trends are deteriorating rather than reassuring.
Reasoning steps for option B
What limited reassurance does the CK fall from 26,000 to 13,000 offer?
It may indicate improving biochemical muscle injury after the peak.
Why is outpatient follow-up inappropriate despite that trend?
Rising creatinine, falling urine output and rising potassium show organ deterioration rather than recovery.
C. Creatinine reflects persistent muscle leakage without kidney risk (Why this does not fit)
Muscle injury can affect several laboratory measurements. Rising creatinine together with oliguria and hyperkalemia is evidence of clinically important renal dysfunction, not a reason to disregard kidney risk.
Reasoning steps for option C
Can muscle injury influence laboratory measurements beyond CK?
Yes, muscle injury can affect several laboratory measurements.
Why can the rising creatinine not be dismissed as mere muscle leakage?
Its rise together with oliguria and hyperkalemia indicates clinically important renal dysfunction.
D. Treatment should await a second rise in CK (Why this does not fit)
Serial CK can identify a changing muscle injury trajectory. The patient already has dangerous organ abnormalities; treatment cannot be deferred until the leakage marker reverses direction.
Reasoning steps for option D
What can serial CK reveal during rhabdomyolysis?
It can show how the muscle-injury marker changes over time.
Must CK rebound before treating this patient?
No. Hyperkalemia, oliguria and worsening renal function already demand monitored intervention.
Takeaway: A falling CK does not make worsening kidney function or hyperkalemia safe. [9]
A. The CK value excludes clinically important muscle injury (Why this does not fit)
A CK result can support an acute muscle-injury diagnosis when interpreted at the appropriate time. Only two hours have passed, so CK may not yet reflect the full injury; the exposure and pigment pattern remain concerning.
Reasoning steps for option A
When is CK useful after an acute crush injury?
An appropriately timed CK can support a diagnosis of muscle injury.
Why does CK 340 two hours after release fail to exclude substantial injury?
CK may lag behind the acute insult; severe pain and pigment-pattern urine remain concerning.
B. The urine findings establish primary glomerular bleeding (Why this does not fit)
Glomerular bleeding usually produces red cells in the urine and may produce red-cell casts. Strong dipstick heme with very few red cells after muscle compression suggests pigment rather than a red-cell bleeding pattern.
Reasoning steps for option B
What urine microscopy would more strongly support glomerular bleeding?
Urinary red cells, potentially including red-cell casts, would support that source.
How does strong heme positivity with only 0 to 2 red cells change the interpretation?
After compression and without hemolysis evidence, the mismatch suggests pigment rather than primary red-cell bleeding.
C. Early muscle injury warrants serial CK and organ-risk testing (Best answer)
CK can lag after acute muscle injury, whereas pigment may appear earlier. The compression history, pain and heme-positive urine with few red cells justify serial CK plus potassium, kidney function, ECG and urine-output assessment.
Reasoning steps for option C
Can pigment appear before CK reaches its later peak?
Yes. Pigment may appear early while CK is still rising after muscle injury.
Which assessments follow from the crush exposure, pain and pigment pattern?
Repeat CK and assess potassium, renal function, ECG and urine output for acute organ risk.
D. A resting repeat in one week is the appropriate next step (Why this does not fit)
A resting repeat can clarify incidental mild hyperCKemia in a clinically well adult. This is an acutely symptomatic compression injury, so the incidental-result strategy would inappropriately delay evaluation.
Reasoning steps for option D
For which CK finding would a rested repeat in a week be reasonable?
An incidental mild elevation in a clinically well adult can be reassessed after rest.
Why does that strategy not fit dark urine two hours after entrapment?
This is symptomatic acute compression injury requiring immediate evaluation, not incidental hyperCKemia.
Takeaway: An early modest CK does not rule out evolving rhabdomyolysis in a symptomatic patient. [9]
A. Repeat muscle biopsy to quantify residual myocyte necrosis (Why this does not fit)
Biopsy can clarify selected questions about muscle pathology. Improving limb findings do not explain the crackles and impaired diffusion, and muscle tissue sampling would not directly assess the lung abnormality.
Reasoning steps for option A
What diagnostic question can repeat muscle biopsy address?
It may clarify selected residual muscle-pathology questions.
Why does it not explain this new cough and impaired diffusion?
Improving strength and CK do not account for crackles, exertional desaturation and reduced diffusion; lung assessment is needed.
B. Obtain high-resolution chest CT with pulmonary testing (Best answer)
Inflammatory myopathy can involve the lung independently of the apparent limb-muscle response. Dry cough, basilar crackles, exertional desaturation and reduced diffusion support assessment for interstitial lung disease.
Reasoning steps for option B
Can lung involvement progress despite better limb strength and CK?
Yes. Inflammatory myopathy lung disease can evolve independently of limb-muscle response.
Which findings justify high-resolution chest CT and pulmonary testing?
Dry cough, bibasilar crackles, walking desaturation and diffusion capacity of 48% predicted support evaluation for interstitial lung disease.
C. Follow CK as the main indicator of respiratory improvement (Why this does not fit)
CK can follow enzyme leakage from injured muscle. It is already improving despite worsening respiratory findings, so it cannot substitute for direct pulmonary assessment.
Reasoning steps for option C
What does CK track in the treated muscle disease?
It tracks skeletal-muscle enzyme leakage rather than pulmonary gas transfer.
Why would following CK alone miss the respiratory problem?
CK is improving while cough, crackles, desaturation and reduced diffusion point to worsening lung disease.
D. Perform repetitive nerve stimulation as the first respiratory test (Why this does not fit)
Repetitive stimulation can identify impaired neuromuscular transmission. The supplied crackles and impaired gas transfer favor parenchymal lung disease rather than an isolated transmission explanation.
Reasoning steps for option D
What mechanism does repetitive nerve stimulation test?
It evaluates impaired neuromuscular transmission.
Why does this presentation favor lung imaging instead?
Basilar crackles and low diffusion capacity indicate a parenchymal gas-transfer problem rather than isolated transmission failure.
Takeaway: Improved limb strength and CK do not establish that lung involvement has resolved. [2]
A. Continue outpatient follow-up while oxygen saturation remains normal (Why this does not fit)
Pulse oximetry helps detect impaired blood oxygenation. A normal saturation does not establish adequate ventilatory reserve or safe secretion clearance in a patient with progressive respiratory muscle weakness.
Reasoning steps for option A
What does the 97% oxygen saturation actually measure?
Pulse oximetry measures blood oxygenation, not ventilatory reserve or secretion clearance.
Why is outpatient observation unsafe despite normal saturation?
Vital capacity is falling and cough and secretion handling are worsening, threatening ventilation and airway protection.
B. Wait for CK to increase before escalating respiratory care (Why this does not fit)
CK reflects muscle enzyme leakage and may help follow active injury. The airway and breathing findings already establish urgency; a further enzyme increase is not needed to justify assessment.
Reasoning steps for option B
What biologic process does CK reflect in necrotizing myopathy?
CK reflects muscle enzyme leakage and can help follow ongoing injury.
Why should respiratory escalation not wait for another CK rise?
Falling vital capacity, weak cough and retained secretions already establish urgent airway and breathing risk.
C. Prescribe supplemental oxygen as the principal treatment (Why this does not fit)
Oxygen treats hypoxemia when present. The immediate problem is declining ventilation and secretion handling, which oxygen alone does not correct.
Reasoning steps for option C
When would supplemental oxygen address the primary abnormality?
Oxygen can treat hypoxemia when it occurs.
Why is oxygen alone inadequate for this patient?
It does not restore declining ventilation or ability to clear secretions, the immediate threats here.
D. Arrange urgent monitored airway and ventilatory assessment (Best answer)
Bulbar and respiratory muscle weakness can threaten airway protection and ventilation before desaturation develops. Weak cough, secretion retention and falling vital capacity require urgent assessment with readiness for respiratory support.
Reasoning steps for option D
Why may bulbar and respiratory weakness be dangerous before desaturation?
Airway protection and ventilatory reserve can fail before oxygen saturation declines.
What action follows from weak cough, secretion retention and falling vital capacity?
Arrange urgent monitored airway and ventilatory assessment with readiness for respiratory support.
Takeaway: Normal oxygen saturation does not establish safe respiratory reserve in a weakening patient. [2]
A. Skeletal muscle contributes to the aminotransferase increases (Best answer)
AST and ALT are present in skeletal muscle as well as the liver. The marked CK increase and parallel course with normal bilirubin and gamma-glutamyl transferase support a muscular contribution, without excluding concurrent liver disease.
Reasoning steps for option A
Are AST and ALT confined to the liver?
No. Skeletal muscle can release both aminotransferases.
What links these elevations to muscle without excluding liver disease?
CK 18,000 and parallel aminotransferase decline, with normal bilirubin and gamma-glutamyl transferase, support a muscle contribution but do not rule out concurrent hepatic disease.
B. The aminotransferases establish primary hepatic necrosis (Why this does not fit)
Hepatocellular injury can cause AST and ALT increases. These enzymes are not liver-specific, and the accompanying muscle injury and parallel enzyme course prevent concluding that primary liver necrosis is established.
Reasoning steps for option B
Could primary hepatocellular injury increase AST and ALT?
Yes, liver-cell injury can raise both enzymes.
Why is primary hepatic necrosis not established here?
AST and ALT are not liver-specific, and severe muscle injury with parallel enzyme declines supplies another plausible source.
C. A cholestatic process explains the entire laboratory pattern (Why this does not fit)
Cholestasis can cause abnormal liver-associated tests. Normal bilirubin and gamma-glutamyl transferase do not support a dominant cholestatic explanation for the muscle-associated enzyme pattern.
Reasoning steps for option C
What does a cholestatic disorder potentially alter?
It can change liver-associated test results.
Why does cholestasis poorly explain this specific pattern?
Normal bilirubin and gamma-glutamyl transferase plus CK-linked aminotransferase changes do not support dominant cholestasis.
D. The AST-to-ALT relationship identifies alcohol-associated hepatitis (Why this does not fit)
An AST-predominant pattern can occur in alcohol-associated liver injury. The ratio alone is nonspecific, and the documented muscle injury offers a direct alternative source for both enzymes.
Reasoning steps for option D
Why might an AST-predominant result raise an alcohol-related hypothesis?
Alcohol-associated liver injury can have AST predominance.
Why is the AST-to-ALT relationship insufficient here?
The ratio is nonspecific, and documented muscle damage can directly raise both enzymes.
Takeaway: Interpret AST and ALT in the muscle context rather than diagnosing liver disease from either alone. [9]
A. Begin empiric glucocorticoids before further testing (Why this does not fit)
Glucocorticoids can treat selected active inflammatory muscle disorders. The stable minimally symptomatic familial pattern with fatty change does not establish active inflammation or justify empiric immunosuppression.
Reasoning steps for option A
When might glucocorticoids treat muscle weakness?
They may treat selected active inflammatory myopathies.
What makes empiric steroids poorly supported in this familial case?
Stable mild symptoms, normal strength and selective fatty MRI change do not establish active inflammation.
B. Repeat CK after exercise before considering inherited disease (Why this does not fit)
Activity-associated measurements can demonstrate exercise-related enzyme release. Persistent abnormality has already been confirmed after rest, and the family and MRI findings warrant a directed inherited-disease evaluation.
Reasoning steps for option B
What could a CK sample collected after exertion demonstrate?
It could show activity-related enzyme release.
Why is another exercise-provoked CK not the next discriminator?
CK remains elevated after rest; the affected sister and selective MRI pattern call for inherited-disease evaluation.
C. Arrange specialist-guided genetic testing with counseling (Best answer)
Genetic testing can identify inherited causes of persistent oligo/asymptomatic hyperCKemia after acquired causes are addressed. The familial pattern, repeated resting results and selective MRI findings favor this approach before routine first-line biopsy.
Reasoning steps for option C
What diagnostic class does specialist-guided genetic testing address?
It can identify inherited causes of persistent oligo/asymptomatic hyperCKemia after acquired causes are considered.
Which findings make genetic testing with counseling preferable to routine initial biopsy?
Repeated rested CK elevation, a similarly affected sister and selective fatty MRI change favor a phenotype-guided inherited workup.
D. Perform a random muscle biopsy before phenotype review (Why this does not fit)
Tissue sampling can clarify selected unresolved inflammatory or metabolic questions. Current evaluation of this stable familial presentation favors phenotype-guided genetic testing rather than an untargeted initial biopsy.
Reasoning steps for option D
When can muscle biopsy still help in a CK evaluation?
It can resolve selected inflammatory or metabolic questions when the phenotype warrants tissue assessment.
Why avoid a random first biopsy in this patient?
The stable familial phenotype favors specialist-guided genetic testing before untargeted tissue sampling.
Takeaway: The stable familial CK pathway differs from the urgent assessment of rapidly progressive weakness. [1]
A. The left quadriceps with severe fatty replacement (Why this does not fit)
An affected muscle can contain evidence of the disease process. Predominantly end-stage fatty tissue may contain too little viable muscle to characterize the active process well.
Reasoning steps for option A
Why might an affected quadriceps initially seem useful for biopsy?
Affected tissue can contain evidence of the underlying muscle disease.
What limits a quadriceps replaced largely by fat?
End-stage replacement may leave too little viable muscle to characterize the active process.
B. The right deltoid with edema and preserved tissue (Best answer)
A moderately affected muscle with viable tissue can provide both active abnormalities and interpretable fiber architecture. The imaging identifies such a site without the severe fatty replacement or recent needle injury affecting the alternatives.
Reasoning steps for option B
What tissue features make the right deltoid informative?
Patchy edema and substantial preserved tissue can reveal active changes while retaining interpretable fiber architecture.
Why choose it over the other MRI sites or the needled muscle?
It is affected yet viable, unlike the fatty quadriceps or normal calf, and avoids recent needle-related artifact.
C. A normal calf muscle without MRI abnormalities (Why this does not fit)
Uninvolved tissue can provide normal architecture for comparison. A clinically and radiologically uninvolved site has a lower chance of capturing the process responsible for proximal weakness.
Reasoning steps for option C
What could a normal calf specimen provide?
It could show normal muscle architecture for comparison.
Why is it a poor target for the current proximal myopathy?
A clinically and radiologically uninvolved muscle is less likely to capture the disease process.
D. The muscle recently examined with a needle electrode (Why this does not fit)
Needle examination can help localize an abnormal muscle. Recent needle injury can introduce confounding tissue changes; another suitable affected site is available.
Reasoning steps for option D
What information did needle electromyography provide?
It helped assess and localize the myopathic abnormality.
Why should the recently needled muscle be avoided for biopsy?
Needle injury can confound histology, and another appropriately affected viable site is available.
Takeaway: When biopsy is needed, select a site that can answer the question rather than simply the weakest muscle. [1]
